CMV Immunity Monitoring in Lung Transplant Recipients
NCT: NCT05708755 · RECRUITING
Brief Summary
The purpose of this study is to determine the safety and feasibility of using a laboratory test to guide duration of antiviral prophylaxis with valganciclovir (medication used to prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell Immunity Panel, measures patients' immune response to a common viral infection known as cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.
Frequently Asked Questions
What is CMV Immunity Monitoring in Lung Transplant Recipients?
CMV Immunity Monitoring in Lung Transplant Recipients is a clinical trial registered under NCT05708755. Current status: RECRUITING.
What is the status of NCT05708755?
The current status of NCT05708755 (CMV Immunity Monitoring in Lung Transplant Recipients) is: RECRUITING.
When did CMV Immunity Monitoring in Lung Transplant Recipients start?
CMV Immunity Monitoring in Lung Transplant Recipients started on 2024-09-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.